Update on targeted therapies for clear cell renal cell carcinoma.

ABSTRACT:

Purpose of review

The article reviews the evolution of targeted therapies for clear cell renal cell carcinoma (RCC) and recent developments in the field. The vast majority of work in kidney cancer deals with clear cell RCC, which is the most common variant of this malignancy. The identification of loss of function of the von Hippel-Lindau protein as the basis for clear cell RCC, in addition to the well designed clinical trials that have ensued, provide an outstanding model for the development of mechanism-based targeted therapy in cancer.

Recent findings

The treatment of advanced and metastatic RCC continues to be a major challenge for uro-oncologists despite the approval of six targeted therapies over the past 5 years. This rapid growth in therapeutic options has brought mu

SUBMITTER: Singer EA 

PROVIDER: S-EPMC3488422 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature